Altshuler David's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 8, 2023
- Accession no.
- 0001209191-23-007827
- Filed
- Feb 8, 2023
- Trade date
- Feb 6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $399.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Altshuler DavidCIK 0001550395 | Officer (EVP, Global Research and CSO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Common Stock | MOption exerciseAcquired | +1,304 | $187.53 | +$244,539.12 | 69,949 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −12 | $300.39 | −$3,604.68 | 69,937 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −70 | $302.00 | −$21,140 | 69,867 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −100 | $303.64F2,F3 | −$30,364 | 69,767 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −349 | $305.08F2,F4 | −$106,472.92 | 69,418 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −620 | $306.70F2,F5 | −$190,154 | 68,798 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −153 | $309.06F2,F6 | −$47,286.18 | 68,645 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Common Stock | MOption exerciseDisposed | −1,304 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 4 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $303.64 (range $303.37 to $304.27).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $305.08 (range $304.72 to $305.43).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $306.70 (range $306.32 to $307.25).
Referenced by the price of 1 transaction in Table I.
- F6
Open market sales reported on this line occurred at a weighted average price of $309.06 (range $308.76 to $309.42).
Referenced by the price of 1 transaction in Table I.